SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
06 5월 2022 - 5:45AM
Business Wire
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full
potential of cell therapies for multiple therapeutic areas, today
announced that the company will host a live R&D investor event
with optional virtual participation on Thursday, May 19, 2022, from
4:05 - 5:30 p.m. ET.
The event will feature presentations on the company’s
point-of-care (POC) manufacturing system, currently in internal
testing, and its potential impact on cell therapy development. The
company will also discuss its first anticipated clinical use in the
SQZ® TAC clinical development program for celiac disease, which has
an FDA investigational new drug application submission planned for
the first half of 2023.
Company leadership will also discuss the collaboration with
STEMCELL Technologies and the development of a research-use-only
Cell Squeeze® system.
The event will include a special fireside chat on the present
and future state of cell engineering. Speakers include:
- Robert S. Langer, Sc.D., Scientific Advisory Board Member and
Founder of SQZ Biotechnologies, and David H. Koch Institute
Professor at the Massachusetts Institute of Technology
- Klavs F. Jensen, Ph.D., Board Member and Founder of SQZ
Biotechnologies, and Warren K. Lewis Professor of Chemical
Engineering at the Massachusetts Institute of Technology
- Armon Sharei, Ph.D., Chief Executive Officer and Founder
of SQZ Biotechnologies
- Moderated by Mike Huckman, Global Practice Leader,
Executive Communications at Real Chemistry, and former CNBC
Pharmaceuticals Reporter
Event Details The company will host a live R&D
Investor event with optional virtual participation on Thursday, May
19, 2022, beginning at 4:05 p.m. ET. Onsite and virtual
participants can register in advance by completing the registration
form on the event website: https://investorday.sqzbiotech.com/.
Following the event, a webcast replay will be made available on the
company’s investor website: investors.sqzbiotech.com.
About SQZ Biotechnologies SQZ Biotechnologies Company is
a clinical-stage biotechnology company focused on unlocking the
full potential of cell therapies for patients around the world and
has active programs in oncology, autoimmune and infectious
diseases, as well as additional exploratory initiatives to support
future pipeline growth. The company’s proprietary Cell Squeeze®
technology offers the unique ability to deliver multiple biological
materials into many cell types to engineer what we believe can be a
broad range of potential therapeutics. With demonstrated production
timelines under 24 hours and the opportunity to eliminate
preconditioning and lengthy hospital stays, our approach could
significantly broaden the therapeutic range and accessibility of
cell therapies. The company’s first therapeutic applications seek
to generate target-specific immune responses, both in activation
for the treatment of solid tumors and infectious diseases, and in
immune tolerance for the treatment of autoimmune diseases. For more
information, please visit www.sqzbiotech.com.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements relating to events and presentations, our platform
development, product candidates, preclinical and clinical
activities, progress and outcomes, development plans, manufacturing
capabilities, clinical safety and efficacy results, therapeutic
potential, collaborations and market opportunities. These
forward-looking statements are based on management's current
expectations. Actual results could differ from those projected in
any forward-looking statements due to several risk factors. Such
factors include, among others, risks and uncertainties related to
our limited operating history; our significant losses incurred
since inception and expectation to incur significant additional
losses for the foreseeable future; the development of our initial
product candidates, upon which our business is highly dependent;
the impact of the COVID-19 pandemic on our operations and clinical
activities; our need for additional funding and our cash runway;
the lengthy, expensive, and uncertain process of clinical drug
development, including uncertain outcomes of clinical trials and
potential delays in regulatory approval; our ability to maintain
our relationships with our third party vendors and strategic
collaborators; and protection of our proprietary technology,
intellectual property portfolio and the confidentiality of our
trade secrets. These and other important factors discussed under
the caption "Risk Factors" in our most recent Annual Report on Form
10-K and other filings with the U.S. Securities and Exchange
Commission could cause actual results to differ materially from
those indicated by the forward-looking statements. Any
forward-looking statements represent management's estimates as of
this date and we undertake no duty to update these forward-looking
statements, whether as a result of new information, the occurrence
of current events, or otherwise, unless required by law.
Certain information contained in this press release relates to
or is based on studies, publications, surveys and other data
obtained from third-party sources and our own internal estimates
and research. While we believe these third-party sources to be
reliable as of the date of this press release, we have not
independently verified, and we make no representation as to the
adequacy, fairness, accuracy or completeness of any information
obtained from third-party sources.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220505006068/en/
Media John Lacey 781-392-5514
john.lacey@sqzbiotech.com
Investors Michael Kaiser
857-760-0398 michael.kaiser@sqzbiotech.com
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024